A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer

Author： Chi Kim   Chia Stephen   Dixon Ross   Newman Michael   Wacher Vince   Sikic Branimir   Gelmon Karen  

Publisher： Springer Publishing Company

ISSN： 0167-6997

Source： Investigational New Drugs, Vol.23, Iss.4, 2005-08, pp. : 311-315

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non–small cell lung cancer

By Okamoto Isamu   Miyazaki Masaki   Morinaga Ryotaro   Kaneda Hiroyasu   Ueda Shinya   Hasegawa Yoshikazu   Satoh Taroh   Kawada Akira   Fukuoka Masahiro   Fukino Koichi   Tanigawa Takahiko   Nakagawa Kazuhiko  

Investigational New Drugs, Vol. 28, Iss. 6, 2010-12 ,pp. : 844-853

Springer Publishing Company

Access to resources Recommend Favorite

Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies

By Deenen Maarten  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1557-1565

Springer Publishing Company

Access to resources Recommend Favorite

Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin–bound paclitaxel in patients with advanced solid tumors

By Abu-Khalaf Maysa M.   Baumgart Megan A.   Gettinger Scott N.   Doddamane Indukala   Tuck David P.   Hou Shihe   Chen Nianhang   Sullivan Catherine   Lezon-Geyda Kimberly   Zelterman Daniel   Hatzis Christos   Deshpande Hari   Digiovanna Michael P.   Azodi Masoud   Schwartz Peter E.   Harris Lyndsay N.  

Cancer, Vol. 121, Iss. 11, 2015-06 ,pp. : 1817-1826

Blackwell Publishing

Access to resources Recommend Favorite

A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy

By Shin Sang  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1501-1510

Springer Publishing Company

Access to resources Recommend Favorite

A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer

By Renouf Daniel  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 779-786

Springer Publishing Company

Access to resources Recommend Favorite